FMP
Eton Pharmaceuticals, Inc.
ETON
NASDAQ
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
11.97 USD
-0.68 (-5.68%)
Latest ETON News
GlobeNewsWire
Aug 22, 2024
Eton Pharmaceuticals to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
DEER PARK, Ill., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced today that the Company will participate at the H.C. Wainwright 26th Annual Global Investment Conference in New York City.
Seeking Alpha
Aug 11, 2024
Eton Pharmaceuticals, Inc. (ETON) Q2 2024 Earnings Call Transcript
Eton Pharmaceuticals, Inc. (NASDAQ:ETON ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants David Krempa - Chief Business Officer Sean Brynjelsen - Chief Executive Officer James Gruber - Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Operator Good afternoon, and welcome to the Eaton Pharmaceuticals Second Quarter 2024 Financial Results Conference Call. [Operator Instructions] Please be advised, this call is being recorded at ...
GlobeNewsWire
Jul 30, 2024
Eton Pharmaceuticals to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
DEER PARK, Ill., July 30, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report second quarter 2024 financial results on Thursday, August 8, 2024. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT).
Seeking Alpha
May 11, 2024
Eton Pharmaceuticals, Inc. Q1 2024 Earnings Call Transcript
Eton Pharmaceuticals, Inc. Q1 2024 Earnings Call Transcript May 9, 2024 4:30 PM ET Company Participants David Krempa - Chief Business Officer Sean Brynjelsen - Chief Executive Officer James Gruber - Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Operator Good afternoon, and welcome to the Eton Pharmaceuticals First Quarter 2024 Financial Results Conference Call. At this time all participants are in listen-only mode.
GlobeNewsWire
May 1, 2024
Eton Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference
DEER PARK, Ill., May 01, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced today that Sean Brynjelsen, Chief Executive Officer, and James Gruber, Chief Financial Officer, will present at the Citizens JMP Life Sciences Conference in New York as follows:
GlobeNewsWire
Apr 29, 2024
Eton Pharmaceuticals to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
DEER PARK, Ill., April 29, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report first quarter 2024 financial results on Thursday, May 9, 2024. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT).
Seeking Alpha
Mar 14, 2024
Eton Pharmaceuticals, Inc. (ETON) Q4 2023 Earnings Call Transcript
Eton Pharmaceuticals, Inc. (ETON) Q4 2023 Earnings Call Transcript
Zacks Investment Research
Mar 14, 2024
Eton Pharmaceuticals, Inc. (ETON) Reports Q4 Loss, Lags Revenue Estimates
Eton Pharmaceuticals, Inc. (ETON) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to earnings of $0.04 per share a year ago.
GlobeNewsWire
Feb 29, 2024
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 14, 2024
DEER PARK, Ill., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report fourth quarter and full year 2023 financial results on Thursday, March 14, 2024. Management will host a conference call and live audio webcast to discuss these results at 4:30 p.m. ET (3:30 p.m. CT).
Zacks Investment Research
Dec 14, 2023
5 Under-$15 Stocks Wall Street Analysts Recommend Buying
After a stellar rally in Wall Street this year, investors with limited funds but desire to participate in the market can bet on low-priced top-ranked stocks like Eton Pharmaceuticals (ETON), LegalZoom.com (LZ), PLAYSTUDIOS (MYPS), American Public Education (APEI) and Cellebrite DI (CLBT).
